stockrowSTAAR Surgical Company
STAA Healthcare Medical Instruments & Supplies
STAAR Surgical Company’s revenue for fiscal 2025 (year ended December 2025) was $239.4 million, down 23.7% from fiscal 2024.
- Revenue
- −12.0%
- EPS
- −38.9%
- Free cash flow
- +1,378.7%
Quarter to September 2026, against a year earlier
Follow STAA
Alert me
STAAR Surgical Company (STAA) EV/Sales
As of 5 November 2026, STAAR Surgical Company (STAA) trades at a EV/Sales of 3.5×. Over the past ten years it has ranged from 1.7× (February 2025) to 39.4× (June 2021); the current reading is higher than 16% of that period. That is above the Medical Instruments & Supplies industry median of 2.8× and in line with the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.1× | 34.73% |
| FY2024 | 3.1× | (19.07%) |
| FY2023 | 3.8× | (52.05%) |
| FY2022 | 7.9× | (55.69%) |
| FY2021 | 17.8× | (15.74%) |
| FY2020 | 21.2× | 119.99% |
| FY2019 | 9.6× | (5.00%) |
| FY2018 | 10.1× | 44.77% |
| FY2017 | 7.0× | 37.70% |
| FY2016 | 5.1× | 46.71% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.9× | (22.61%) |
| Jun 2026 | 3.8× | 38.14% |
| Mar 2026 | 2.8× | (33.28%) |
| Dec 2025 | 4.1× | (16.49%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NNNN Anbio Biotechnology compare | n/m |
| XRAY DENTSPLY SIRONA Inc. compare | 1.1× |
| ANGO AngioDynamics, Inc. compare | 1.6× |
| AZTA Azenta, Inc. compare | 2.3× |
| WRBY Warby Parker Inc. compare | 3.2× |
| STAA STAAR Surgical Company | 3.5× |
| ATRC AtriCure, Inc. compare | 4.9× |
| LMAT LeMaitre Vascular, Inc. compare | 6.2× |
| KMTS Kestra Medical Technologies, Ltd. compare | 14.2× |
| Medical Instruments & Supplies industry median | 2.8× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)